APS.TO - Aptose Biosciences Inc.

Toronto - Toronto Delayed Price. Currency in CAD
3.2800
+0.1700 (+5.47%)
At close: 3:53PM EST
Stock chart is not supported by your current browser
Previous Close3.1100
Open3.2400
Bid3.2400 x 0
Ask3.2800 x 0
Day's Range3.2400 - 3.3500
52 Week Range2.0800 - 4.0700
Volume6,501
Avg. Volume16,340
Market Cap181.996M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.5530
Earnings DateNov 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.67
  • Is Aptose Biosciences (TSE:APS) In A Good Position To Deliver On Growth Plans?
    Simply Wall St.

    Is Aptose Biosciences (TSE:APS) In A Good Position To Deliver On Growth Plans?

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • GlobeNewswire

    Aptose to Present at BIO-Europe Conference

    SAN DIEGO and TORONTO, Nov. 07, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

  • GlobeNewswire

    Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting

    – Company to Hold Event During ASH –  – CG-806 Preclinical Abstracts Accepted for Presentation – SAN DIEGO and TORONTO, Nov. 06, 2019 -- Aptose Biosciences Inc. (“Aptose”).

  • Thomson Reuters StreetEvents

    Edited Transcript of APS.TO earnings conference call or presentation 5-Nov-19 10:00pm GMT

    Q3 2019 Aptose Biosciences Inc Earnings Call

  • GlobeNewswire

    Aptose Reports Results for the Third Quarter Ended September 30, 2019

    CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate CLL Patient Treated with Second Dose Level of CG-806 Shows Evidence of Clinical.

  • GlobeNewswire

    Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019

    SAN DIEGO and TORONTO, Oct. 22, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target.

  • GlobeNewswire

    Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)

    SAN DIEGO and TORONTO, Oct. 10, 2019 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.

  • GlobeNewswire

    Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies

    SAN DIEGO and TORONTO, Sept. 16, 2019 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.

  • How Much Are Aptose Biosciences Inc. (TSE:APS) Insiders Spending On Buying Shares?
    Simply Wall St.

    How Much Are Aptose Biosciences Inc. (TSE:APS) Insiders Spending On Buying Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Thomson Reuters StreetEvents

    Edited Transcript of APS.TO earnings conference call or presentation 6-Aug-19 9:00pm GMT

    Q2 2019 Aptose Biosciences Inc Earnings Call

  • GlobeNewswire

    Aptose Reports Results for the Second Quarter Ended June 30, 2019

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three months ended June 30, 2019 and reported on corporate developments. The net loss for the quarter ended June 30, 2019 was $6.2 million ($0.13 per share) compared with $10.3 million ($0.30 per share) for the quarter ended June 30, 2018. Total cash and cash equivalents and investments as of June 30, 2019 were $35.4 million.

  • GlobeNewswire

    Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference

    SAN DIEGO and TORONTO, July 30, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the.

  • GlobeNewswire

    Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019

    SAN DIEGO and TORONTO, July 23, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target.

  • GlobeNewswire

    Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253

    SAN DIEGO and TORONTO, July 16, 2019 (GLOBE NEWSWIRE) --  Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that dosing of CG-806, the company’s highly potent, first-in-class pan-FLT3/pan-BTK inhibitor, has commenced its Phase 1a/b dose-escalation study in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or non-Hodgkin lymphomas (NHL) who have failed or are intolerant to standard therapies. In parallel, the company has successfully completed the first two dose levels of the Phase 1b clinical trial of MYC inhibitor APTO-253, and is now dosing the third dose cohort. Initial data from the first two cohorts demonstrate MYC inhibition in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

  • Thomson Reuters StreetEvents

    Edited Transcript of APS.TO earnings conference call or presentation 7-May-19 9:00pm GMT

    Q1 2019 Aptose Biosciences Inc Earnings Call

  • GlobeNewswire

    Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new preclinical data for CG-806, its oral, first-in-class pan-FLT3/pan-BTK inhibitor, is being presented in a poster presentation today at the 24th Congress of the European Hematology Association in Amsterdam, the Netherlands. In the mice treated with 100 mg/kg, 5 of 11 (45%) were cured through day 120, and in the 300 mg/kg group, 10 of 11 (91%) of the mice were cured. Retreating the “uncured’ mice in these two dose groups for an additional 28 days beginning on day 88 led to rapid and robust antitumor response resulting in “cures” in all retreated mice through day 120.

  • Could The Aptose Biosciences Inc. (TSE:APS) Ownership Structure Tell Us Something Useful?
    Simply Wall St.

    Could The Aptose Biosciences Inc. (TSE:APS) Ownership Structure Tell Us Something Useful?

    If you want to know who really controls Aptose Biosciences Inc. (TSE:APS), then you'll have to look at the makeup of...

  • GlobeNewswire

    Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders

    SAN DIEGO and TORONTO, June 04, 2019 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.

  • GlobeNewswire

    Aptose Appoints Jotin Marango, M.D., Ph.D. as Chief Business Officer

    Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Jotin Marango, M.D., Ph.D., to the position of Senior Vice President, Chief Business Officer, effective immediately. In his role as a member of the executive leadership team, Dr. Marango is responsible for Aptose’s corporate and business development initiatives, including licensing and alliance management, business and product strategy, as well as market and competitive intelligence. “Joti’s deep understanding of the biotechnology landscape and hematology/oncology space specifically, will serve Aptose well during this next phase of corporate development and as our investigational products approach important clinical milestones,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.

  • GlobeNewswire

    Aptose Announces Closing of Public Offering of Common Shares

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares at a price to the public of $1.85 per share, including the exercise in full by the underwriters of their option to purchase 1,500,000 additional common shares. Aptose intends to use the net proceeds of the offering to accelerate and expand its clinical trial programs, and for working capital and general corporate purposes. RBC Capital Markets and Canaccord Genuity acted as joint book-running managers for the offering.  H.C. Wainwright & Co. and JonesTrading Institutional Services LLC acted as co-managers.

  • GlobeNewswire

    Aptose to Present at the Jefferies 2019 Healthcare Conference

    SAN DIEGO and TORONTO, May 31, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the.

  • GlobeNewswire

    Aptose Announces Pricing of Public Offering of Common Shares

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 10,000,000 common shares at a price of $1.85 per share (the “Offering”) before deducting underwriting discounts and commissions. Gross proceeds from the offering of these shares, before deducting underwriting discounts and commissions, are expected to be $18.5 million. The underwriters have been granted a 30-day option to purchase up to 1,500,000 additional common shares in the Offering.

  • GlobeNewswire

    Aptose Announces Proposed Public Offering of Common Shares

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its Common Shares (the “Offering”). In addition, Aptose intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the common shares offered in the Offering. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • GlobeNewswire

    Aptose Biosciences Establishes New At-The-Market Facility

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that it has entered into an “at-the-market” (“ATM”) sales agreement (the “Sales Agreement”) with Piper Jaffray and Canaccord Genuity (collectively “Co-Agents”). Under the terms of the Sales Agreement, the Company may, from time to time, issue and sell through the Co-Agents, common shares of the Company (the “Common Shares”) through ATM distributions (the “Offering”) on the NASDAQ Capital Market (“NASDAQ”).

  • GlobeNewswire

    Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association

    SAN DIEGO and TORONTO, May 16, 2019 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.